Kevin is our Vice President, Biology. He previously held roles at Bayer, Merck and Janssen leading groups performing preclinical small molecule and peptide drug discovery. Kevin has worked in preclinical pharmacology roles from target validation to development candidate nomination. He established groups for peptide discovery at Bayer and for lead discovery at both Merck and Janssen. He has published 54 papers, the vast majority of which as a senior author. He obtained a BSc in Chemistry at University College London and a DPhil at the University of Oxford under the tutelage of Sir Christopher M. Dobson, followed by postdoctoral studies at the Whitehead Institute at MIT with Professor Peter S. Kim.